Item 8.01 Other Events
ChemoCentryx, Inc, (the "Company") previously announced that the $45.0 million
non-refundable milestone payment received in the first quarter of 2022 in
connection with the TAVENOS approval in the European Union will be recognized as
collaboration revenue under accounting guidelines, including ASC606. Such
recognition will occur over an estimated four year period, subject to adjustment
from time to time.
This results from the Company and Vifor Fresenius Medical Care Renal Pharma Ltd.
(the "VFMCRP") having conditionally nominated lupus nephritis in the first
quarter of 2022 as the third and final indication under the Collaboration and
License Agreement, dated May 9, 2016 as amended, pursuant to which the Company
granted VFMCRP an exclusive license to commercialize the Company's proprietary
C5aR inhibitor CCX168, and now approved as TAVNEOS® (avacopan).
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
CHEMOCENTRYX, INC. 
